Latest:
Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC
Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Cora Sternberg, MD, FACP, Weill Cornell Medicine
Latest:
ESMO 2020 Highlights With Cora Sternberg, MD, FACP
TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
Jane Delartigue, PhD
Latest:
Tumor Agnostic Role of TMB Biomarker Faces Challenges
Although tumor mutational burden is established as a clinically informative feature of tumors, its optimal use in therapeutic decision-making faces many challenges, and we are only beginning to fully understand its strengths and limitations.
Jean-Marie Michot, MD
Jean-Marie Michot, MD, is a medical doctor in the Department of Hematology and Innovative Drugs at the Institut de Cancérologie Gustave Roussy.
Latest:
Dr Michot on the Importance of the OLYMPIA-3 Study of Odronextamab Plus Chemo in DLBCL
Jean-Marie Michot, MD, discusses the OLYMPIA-3 study investigating odronextamab plus CHOP in previously untreated diffuse large B-cell lymphoma.
Jose Tinajero, PharmD, BCOP
Jose Tinajero, PharmD, BCOP is a bone marrow transplant and hematology clinical pharmacist at City of Hope in Duarte, California.
Latest:
Dr Tinajero on the Role of Pharmacists in Treatment Planning and Management in CML
Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.
Shirley D'Sa, MD, FRCP, FRCPath
Latest:
Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study
Dr. Shirley D’Sa highlights the 5.8-year follow-up results from the ASPEN long-term extension study, demonstrating the durable efficacy, deepening responses, and favorable safety profile of zanubrutinib in patients with Waldenström macroglobulinemia, including those with high-risk genetic mutations.
Susumu Hijioka, MD, PhD
Susumu Hijioka, MD, PhD, works in the Department of Hepatobiliary and Pancreatic Oncology at National Cancer Center, in Japan.
Latest:
Dr Hijoka on Updated Efficacy Data With Everolimus Plus Lanreotide in GEP-NETs
Susumu Hijioka, MD, PhD, discusses the efficacy of first-line everolimus plus lanreotide in patients with unresectable or recurrent GEP-NETs.
Asad Dean, MD
Asad Dean, MD, is a physician at Texas Oncology and an assistant professor in the Division of Hematology/Oncology at UT Southwestern Medical Center.
Latest:
The Evolving Role of Noncovalent BTK Inhibition Informs CLL Treatment Selection: With Asad Dean, MD
Dean discusses the role of BTK inhibitors in the management of CLL and the importance of molecular profiling for treatment rechallenge decisions.